Cofetuzumab
Based on 1 Customer Validation
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is typically CHO (Chinese hamster ovary) cells. Cofetuzumab downregulates PTK7 expression, modulates its downstream signaling pathways, and inhibits tumor sphere formation of ovarian cancer cells. Cofetuzumab can be used to synthesize the ADC molecule Cofetuzumab pelidotin (HY-P99829). Cofetuzumab is applicable to the research of tumors such as ovarian cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.31%
- CAS 番号: 1869928-62-0
- 分子量:146.7 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
Human IgG1 kappa
Human
PTK7/CCK4
Cofetuzumab (10 μg/mL; 48 h) upregulates pERK1/2 in FIMM-PDC1-PDC3, and simultaneously upregulates ROR1 expression in FIMM-PDC3 with high PTK7 expression[1].
Cofetuzumab (10 μg/mL; 48 h) downregulates the expression level of SNCG protein in Kuramochi cells and FIMM-PDC1 cells[1].
Cofetuzumab (20 μg/mL; 5 days) inhibits tumor sphere formation and induces more dispersed structures in JHOS2, Kuramochi, FIMM-PDC3 and FIMM-PDC7 cells[1].
Cofetuzumab (10 μg/mL; 24 h) exerts synergistic cytotoxicity with Prexasertib (HY-18174) and Paclitaxel (HY-B0015) in FIMM-PDC3 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Kuramochi (high-grade serous ovarian cancer cell line), FIMM-PDC1 (high-grade serous ovarian cancer patient-derived cell culture)
-
Concentration:10 μg/mL
-
Incubation Time:48 h
-
Result:Downregulated synuclein-γ (SNCG) protein levels in both cell models.
Q13308-1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized Human PTK7/CCK4, Fc Tag can bind Cofetuzumab. The EC50 for this effect is 21.74 ng/mL. -
Flow Cytometry analysis of Hela cells labelling PTK7/CCK4 (red) with Cofetuzumab (anti-PTK7/CCK4) (HY-P99828). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
化学情報
-
CAS 番号 1869928-62-0
-
性状 Liquid
-
分子量 146.7 kDa
-
Color Colorless to light yellow
-
SMILES
[Cofetuzumab]
-
別名
PF-06523435; hu24
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)